Literature DB >> 11724724

Evaluation of an early two-dose measles vaccination schedule.

S S Hutchins1, A Dezayas, K Le Blond, J Heath, W Bellini, S Audet, J Beeler, W Wattigney, L Markowitz.   

Abstract

Vaccination at 6 months of age followed by routine revaccination is recommended when exposure of infants to measles is likely. Dade County, Florida, began this early two-dose schedule during a large epidemic in 1986-1987 (i.e., 22% of cases occurred in infants aged 6-11 months). This schedule was continued routinely in high-risk areas. The effect of an early two-dose schedule on measles prevention in the county was examined by comparing measles vaccination coverage and epidemiology before (1985-1987) and after (1988-1996) the schedule became routine. To assess serologic response, seroprevalence of measles antibody among children aged 4-6 years in 1995 was examined. To evaluate vaccine effectiveness, a case-control study was conducted among preschool-aged children. Among those aged 2 years, vaccination coverage with > or =1 dose increased from 75% to 94% in 1996. The number of annual cases declined, and endemic measles transmission reportedly ended after 1993. Seroprevalence of plaque reduction neutralization antibody (titer > 1:120) among those receiving vaccination according to an early two-dose schedule and a single dose at age > or =12 months was 94% (95% confidence interval: 89, 98) and 98% (95% confidence interval: 95, 100). In these groups, vaccine effectiveness was comparably high. Early two-dose measles vaccination is associated with improved coverage and a comparably high level of humoral immunity and clinical protection as a single dose at age > or =12 months. This strategy can be useful in areas at high risk for measles among infants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724724     DOI: 10.1093/aje/154.11.1064

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  9 in total

1.  Exposure-measurement error is frequently ignored when interpreting epidemiologic study results.

Authors:  Anne M Jurek; George Maldonado; Sander Greenland; Timothy R Church
Journal:  Eur J Epidemiol       Date:  2006-12-21       Impact factor: 8.082

2.  HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Steven J Jacobsen; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-01-27       Impact factor: 2.846

3.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

4.  Quantifying child mortality reductions related to measles vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Marc Lipsitch; Ajay Mahal; Alan M Zaslavsky; Joshua A Salomon
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

5.  Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Authors:  Hayley A Gans; Linda L Yasukawa; Phillip Sung; Barbara Sullivan; Ross DeHovitz; Susette Audet; Judy Beeler; Ann M Arvin
Journal:  J Infect Dis       Date:  2013-01-08       Impact factor: 5.226

6.  Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998.

Authors:  Mazaher Khodabandeh Loo; Farzaneh Sabahi; Horieh Soleimanjdahi; Anooshirvan Kazemnejad; Mohammod Hassan Roustai
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

7.  Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.

Authors:  Jainaba Njie-Jobe; Samuel Nyamweya; David J C Miles; Marianne van der Sande; Syed Zaman; Ebrima Touray; Safayet Hossin; Jane Adetifa; Melba Palmero; Sarah Burl; David Jeffries; Sarah Rowland-Jones; Katie Flanagan; Assan Jaye; Hilton Whittle
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

8.  Do children who receive an 'early dose' of MMR vaccine during a measles outbreak return for their regularly scheduled dose? A retrospective population-based study.

Authors:  Xiaoyan Guo; Kimberley A Simmonds; Jill Svenson; Shannon E MacDonald
Journal:  BMJ Open       Date:  2016-08-31       Impact factor: 2.692

Review 9.  The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review.

Authors:  Stephanie L Hughes; Shelly Bolotin; Sumaiya Khan; Ye Li; Caitlin Johnson; Lindsay Friedman; Andrea C Tricco; Susan J M Hahné; Jane M Heffernan; Alya Dabbagh; David N Durrheim; Walter A Orenstein; William J Moss; Mark Jit; Natasha S Crowcroft
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.